Liquid-Gas Phase Transition Actuator: Rejuvenation Procedure Extended and Open-Air Performance.

To achieve the actuation of silicone-based foamed composites, a liquid-gas phase transition of the liquid captured in its pores is employed. The uncertainty of key parameters for a single or sequential open-air performance of such soft actuators limits their application. To define the main characteristics of the composites, in this work, two functions of the liquid there were separated: the pore-forming agent (FPA) and working liquid (WL).

Biopsy vitrification: New tool for endometrial tissue cryopreservation for research applications.

Patient-derived endometrial biopsies serve as a crucial source for molecular studies, highlighting the necessity for tissue cryopreservation methods that preserve cell viability and tissue morphology with minimal to no impact. The passive slow freezing (PSF) protocol has demonstrated efficacy for cryopreserving endometrial biopsies, allowing for the subsequent isolation of viable epithelial and stromal cells. Vitrification (VT) enables the avoidance of ice crystal formation and could therefore potentially prevent mechanical injury to tissues.

Cyclodextrin-Polymethylsilsesquioxane Combined System as a Perspective Iron Delivery System for Oral Administration.

Anemia is a global health problem that affects both adults and children, but treatment is hampered by serious side effects, primarily associated with the gastrointestinal tract with oral administration of drugs. In this study, we aimed to develop an oral form of iron compounds using polymethylsilsesquioxane hydrogels. To boost loading efficiency and prolong release, the iron compounds (FeCl and ferrous D-Gluconate) are incorporated into a guest-host complex with 2-hydroxypropyl-beta-cyclodextrin.

Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo.

Purpose: Different regimens of low-dose chemotherapy (LDC) are currently being actively developed and introduced into clinical practice. Along with its obvious advantages compared to conventional chemotherapy (low toxicity, prevention of drug resistance), LDC could also stimulate anti-tumor immune responses in a patient by activating effectors of innate and adaptive immunity and diminishing tumor-associated immunosuppression. As non-myeloablative, LDC could be successfully combined with different anti-cancer immunotherapeutic strategies, including immunoregulatory cytokines.